ANTIBODY DRUG CONJUGATES MARKET ANALYSIS

Antibody Drug Conjugates Market, By Product Type (Adcetris, Kadcyla, Enhertu, Trodelvy, Padcev, Others), By Linker Type (Non-cleavable Linker, Cleavable Linker), By Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023
Code : CMI181
Pages :210
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Antibody Drug Conjugates Market: Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global antibody drug conjugates market over the forecast period. North America is estimated to hold 37.7% of the market share in 2023. The North American antibody drug conjugates market is expected to witness significant growth in the coming years, driven by new product launches or approvals. For instance, in April 2021, ADC Therapeutics SA, a next-generation biotechnology company focused on oncology, announced that the U.S. Food and Drug Administration (FDA) had approved ZYNLONTA (Loncastuximab Tesirinelpyl) for the treatment of relapsed or refractory large B-cell lymphoma. ZYNLONTA, a CD19-targeted antibody-drug conjugate, received accelerated approval from the U.S. FDA based on its overall response rate.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa